Award-Winning Science: Path Fertility Recognized at ASRM 2025 for Breakthrough Male Fertility Research
Kristin Brogaard, PhD receiving the Society for Male Reproduction 2025 Prize Paper Award
This week at the 2025 ASRM Scientific Congress & Expo in San Antonio, Path Fertility presented compelling research that underscores the expanding role of male-focused diagnostics in reproductive medicine. While traditional fertility care has historically centered on female factors, our data continues to demonstrate that precision insights on the male side can meaningfully improve treatment selection, success rates, and cost-efficiency for patients and providers alike.
A Non-Invasive Assay for Predicting Sperm Retrieval Outcomes and Identifying Klinefelter’s Syndrome in Men with NOA: Single-Molecule Native Methylation Sequencing of Sperm-Specific Cell-Free DNA
🏆 Awarded the 2025 Prize Paper Award
Leading our contributions this year, this oral presentation introduces a first-of-its-kind, non-invasive approach for evaluating men with non-obstructive azoospermia (NOA). Today, many of these patients face invasive micro-TESE procedures with uncertain outcomes. Our findings suggest this assay may help identify who is most likely to benefit and detect underlying genetic syndromes earlier in the diagnostic journey. Selection for the prestigious Prize Paper Award highlights both scientific significance and clinical potential.
Preliminary Analysis of a Prospective Cohort Study of an Epigenetic Sperm Quality Test (“SpermQT”) to Predict Success Rates of Ovarian Stimulation Treatment
Presented by Dr. Dana Siegel, M.D. from Shady Grove Fertility, this interim data from the SPOT clinical trial highlights consistent clinical diagnostic performance of our SpermQT assay for predicting pregnancy. The evidence shows that epigenetic sperm quality profiling can help predict which couples are more likely to succeed with ovarian stimulation including timed intercourse, spontaneous pregnancy and intrauterine insemination, reducing time, cost, and emotional burden on couples seeking to build their families.
Comparison of Sperm Methylation in Infertile Men With and Without Clinical Varicocele
This analysis, presented by Dr. Taylor Kohn, M.D. from Baylor College of Medicine, examined differences in sperm methylation signatures associated with one of the most common and treatable male fertility conditions. These findings provide new insight into how epigenetic patterns may contribute to impaired sperm function and how diagnostic precision could personalize treatment decisions, including when to consider surgical repair.
Together, these presentations reinforce a critical message: male fertility is measurable, actionable, and medically significant. They further validate that epigenetic biomarkers can fill longstanding diagnostic gaps and guide more effective, less-invasive care.
Path Fertility remains committed to advancing clinical evidence, partnering with leading physicians, and elevating the standard of care for men, an area that has been largely overlooked for decades. We look forward to sharing additional data, continuing to publish in peer-reviewed journals, and bringing forward innovations that materially improve outcomes for patients and providers.
